P2.09. VRN110755, A New Therapeutic Option for EGFR Mutation-Driven NSCLC with Brain Metastasis or 1st-line Osimertinib-Resistant EGFR Mutations - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Sunghwan Kim
Meta Tag
Speaker Sunghwan Kim
Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2
metastatic non-small cell lung cancer
EGFR mutations
brain metastasis
osimertinib resistance
therapeutic option
EGFR therapies
kinase selectivity
in vivo efficacy
Powered By